Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real ...

The Decipher Prostate test is already widely used in the US to help identify localised prostate cancer more likely to spread. It becomes the first molecular test with clinical evidence from a ...

Truqap extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer compared to placebo, with a median rPFS of 33.2 months. Truqap was associated with higher rates of ...

A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center's Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology ...